BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

PROGRAM

2024 Investment Summit Agenda

​​

Investment Summit Agenda

Venue TaiNEX2 7F

July 24 - WednesdayMedTech & Digital Health
July 25 - ThursdayTherapeutics & Pharmaceuticals

Time

Session

123
09:00 – 13:50

PLENARY Session 1 - 3

Time

Session 1

123
14:10 – 14:15

Opening Remarks

14:15 – 14:30

MedTech and Digital Health

Jorge Cortell
Senior Advisor Health & Life Sciences,
Harvard University Innovation Laboratories

14:30 – 15:40
  1. aetherAI
  2. AIxMed
  3. ANEUVO
  4. APrevent Medical
  5. BioAro
  6. Bonraybio
  7. Brain Navi Biotechnology

Time

Session 2

123
16:30 – 17:30
  1. FaceHeart
  2. Flat Medical
  3. Genialis
  4. HCmed Innovations
  5. Health2Sync
  6. JelloX Biotech
  7. Oxipit
  8. Point Robotics MedTech
  9. 3R Life Sciences
 

Closing Remarks

Time

Session 3

123
09:00 – 10:30

Opening Remarks

  1. AcadeMab Biomedical
  2. Accelerated Biosciences
  3. Acepodia
  4. AiViva BioPharma
  5. Allgenesis Biotherapeutics
  6. AmMax Bio
  7. AnHorn Medicines
  8. AnnJi Pharmaceutical

Time

Session 4

123
10:45 – 12:15
  1. AP Biosciences
  2. Apexcella Biomedical
  3. Apeximmune Therapeutics
  4. Bio-Thera Solutions
  5. Cellusion
  6. Cyto-Facto
  7. De novo Biotherapeutics
  8. DotBio
  9. Elixiron Immunotherapeutics

Time

Session 5

123
12:25 – 13:50

Panel Discussion

Innovative Investment Strategies for New Drug Development

  • Alice Chen, PhD, Executive VP, Accelerator Life Science Partner
  • Gaurev Aggarwal, MD, Managing Partner, Vivo Capital
  • Gur Roshwalb, MD/PhD, Partner, aMoon
  • John Tsai, MD, Executive Partner, Syncona
  • Yenchen Huang, VP, Dimond Biofund

Time

Session 6

123
14:10 – 15:40
  1. GEXVal
  2. HanchorBio
  3. Help Therapeutics
  4. Immunwork
  5. LBL Biotech
  6. Lumosa Therapeutics
  7. OBI Pharma
  8. Ochre Bio
  9. Onward Therapeutics

Time

Session 7

123
16:00 – 17:30
  1. REGiMMUNE
  2. Rock BioMedical
  3. TMS
  4. TriArm
  5. TWi Biotechnology
  6. United Immunity
  7. Xgene Pharmaceutical
  8. XWPharma
 

Closing Remarks